Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Immunol. 2002 Oct;14(5):549-52.

Opportunities and obstacles in developing a vaccine for Entamoeba histolytica.

Author information

  • 1Department of Internal Medicine, University of Virginia, Charlottesville, VA 22908, USA.

Abstract

The development of a vaccine against Entamoeba histolytica, the causative agent of amebic colitis and liver abscess, would reduce childhood mortality in countries such as Bangledesh where community-based studies have demonstrated a high prevalence of E. histolytica. Immunological studies from this population have shown that protection from amebiasis is associated with mucosal anti-E. histolytica Gal/GalNAc lectin antibodies, suggesting that a vaccine is an achievable goal. However, garnering resources for vaccine development is a challenge when the vaccine is targeted to poor people living in developing countries.

PMID:
12183151
[PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk